BiotechTube

AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + Topotecan

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epithelial Ovarian Cancer

Conditions

Epithelial Ovarian Cancer

Trial Timeline

Dec 29, 2025 → May 27, 2030

NCT ID
NCT07218809

About AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + Topotecan

AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + Topotecan is a phase 3 stage product being developed by AstraZeneca for Epithelial Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07218809. Target conditions include Epithelial Ovarian Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07218809Phase 3Recruiting

Competing Products

20 competing products in Epithelial Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
LY2228820 + Carboplatin + Placebo + GemcitabineEli LillyPhase 1/2
41
gemcitabine + carboplatin + paclitaxelEli LillyPhase 2
52
PemetrexedEli LillyPhase 2
52
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
52
Mirvetuximab Soravtansine + Paclitaxel + Topotecan + Pegylated liposomal doxorubicinAbbViePhase 3
77
Carboplatin + Mirvetuximab Soravtansine + BevacizumabAbbViePhase 2
52
Mirvetuximab SoravtansineAbbViePhase 2
52
AvelumabAstraZenecaPhase 2
52
Active Comparator: Olaparib tablets + PlaceboAstraZenecaPhase 3
77
Olaparib + carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weeklyAstraZenecaPhase 2
52
Olaparib + BevacizumabAstraZenecaApproved
85
Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™MerckPhase 3
77
PembrolizumabMerckPhase 2
52
MK-1775 and carboplatinMerckPhase 2
52
GardasilMerckPhase 1
33
NG-350A plus PembrolizumabMerckPhase 1
33
Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant)MerckPhase 3
77
V501MerckPhase 3
77
9-valent HPV vaccinationMerckPhase 2
52
Human Papillomavirus vaccineMerckPhase 2
52

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85